abstract |
The present invention relates to cytokeratin17-specific human antibodies, specifically, complementarity determining regions (CDRs) and framework regions derived from humans that specifically bind to cytokeratin17. , FR). The human antibody specific for the cytokeratin 17 of the present invention can be used for diagnosis of cancer diseases over which the cytokeratin 17 is overexpressed, classification of diseases, imaging, treatment, and prognosis. |